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Abstract
A	nationwide	pretest–posttest	study	was	conducted	in	all	clinical	genetic	centres	in	the	
Netherlands,	to	evaluate	the	effects	of	an	online	decision	aid	to	support	persons	who	
have	a	genetic	predisposition	to	cancer	and	their	partners	in	making	an	informed	decision	
regarding	reproductive	options.	Main	outcomes	(decisional	conflict,	knowledge,	realistic	
expectations,	level	of	deliberation,	and	decision	self‐efficacy)	were	measured	before	use	
(T0),	immediately	after	use	(T1),	and	at	2	weeks	(T2)	after	use	of	the	decision	aid.	Paired	
sample	 t	 tests	were	 used	 to	 compute	 differences	 between	 the	 first	 and	 subsequent	
measurements.	T0–T1	and	T0–T2	comparisons	indicate	a	significant	reduction	in	mean	
decisional	conflict	scores	with	stronger	effects	for	participants	with	high	baseline	deci‐
sional	 conflict.	 Furthermore,	 use	 of	 the	 decision	 aid	 resulted	 in	 increased	 knowledge	
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1  | INTRODUC TION
Most	 hereditary	 cancer	 syndromes	 follow	 an	 autosomal‐dom‐
inant	 inheritance	 pattern,	 implying	 that	 there	 is	 a	 50%	 risk	 of	
transmitting	a	pathogenic	variant	to	offspring,	with	a	high	risk	of	
a	future	malignancy	as	a	consequence.	For	the	relatively	frequent	
breast	 cancer	 gene	mutations	 in	BRCA1 or BRCA2,	 this	 implies	
risks	of	27%–57%	and	6%–40%	of	developing	breast	respectively	
ovarian	 cancer	 by	 the	 age	 of	 70	 (Brohet	 et	 al.,	 2014;	 Chen	 &	
Parmigiani,	2007).	Persons	having	a	genetic	predisposition	to	can‐
cer	and	their	partners	have	to	make	fundamental	decisions	about	
future	 reproduction	 and	 face	 difficult	 challenges	 (Dekeuwer	 &	
Bateman,	2013;	Derks‐Smeets	et	al.,	2014;	Donnelly	et	al.,	2013;	
van	Asperen	 et	 al.,	 2002).	Couples	 have	 three	options	 to	 fulfill	
their	wish	for	a	child	that	 is	genetically	related	to	both	parents.	
The	 first	 option	 is	 natural	 conception	 without	 genetic	 testing,	
implying	acceptance	or	 taking	the	risk	of	passing	on	the	patho‐
genic	 variant.	 Furthermore,	 there	 are	 two	 options	 for	 having	 a	
genetically	 related	 child	 to	 both	 parents	 without	 a	 pathogenic	
variant.	 The	 first	 option	 is	 natural	 conception	with	prenatal	 di‐
agnosis	(PND),	offering	the	choice	to	terminate	the	pregnancy	if	
the	fetus	has	the	pathogenic	variant	(de	Die‐Smulders,	de	Wert,	
Liebaers,	 Tibben,	&	Evers‐Kiebooms,	 2013).	 The	 second	option	
is	 preimplantation	genetic	 diagnosis	 (PGD).	PGD	offers	 the	op‐
tion	 to	obtain	embryos	by	 in	vitro	 fertilization	 (IVF)	and	screen	
them	for	the	familial	pathogenic	variant.	Only	embryos	without	
the	 pathogenic	 variant	 are	 transferred	 into	 the	 uterus	 (de	Die‐
Smulders	 et	 al.,	 2013).	 Levels	 of	 awareness	 for	 PND	 (61%)	 and	
PGD	 (66%)	 are	 similar,	 and	 couples	 consider	 PGD	 (80%)	 to	 be	
more	acceptable	 for	hereditary	cancer	compared	 to	PND	 (26%)	
(Gietel‐Habets	et	al.,	2017).
Couples	 may	 experience	 difficulties	 with	 reproductive	 de‐
cision‐making	 (Dekeuwer	 &	 Bateman,	 2013;	 Dommering	 et	 al.,	
2010;	Ormondroyd	et	al.,	2012),	and	it	was	reported	that	for	some,	
even	years	later,	the	impact	of	reproductive	decision‐making	still	
had	an	 influence	on	 their	 lives	at	a	daily	basis	 (Derks‐Smeets	et	
al.,	2014).	 In	deliberating	the	options,	couples	consider	personal	
values	and	 (dis)advantages	of	 the	options,	 such	as	physical	 (e.g.,	
burden	of	PGD	treatment),	psychological	(e.g.,	loss	of	sense	of	ro‐
mance),	social	(e.g.,	elimination	of	the	pathogenic	variant	in	family	
line),	ethical	 (e.g.,	moral	duty	 to	protect	 the	child),	 and	practical	
considerations	(e.g.,	reimbursement	of	treatment)	(Derks‐Smeets	
et	al.,	2014).	Which	reproductive	option	suits	 them	best,	should	
ideally	 be	 decided	 in	 an	 informed	 decision‐making	 process	 by	
an	 educated	 and	 empowered	 couple,	 supported	 by	 a	 dedicated	
health	 care	 provider.	 In	 order	 to	 promote	 informed	 reproduc‐
tive	 decision‐making,	 the	 use	 of	 decision	 aids	 can	 be	 effective	
(Derks‐Smeets	 et	 al.,	 2014;	 Juraskova	 et	 al.,	 2014;	 O'Connor	 &	
Jacobsen,	2003;	Quinn	et	al.,	2010;	Stacey	et	al.,	2017).	The	pres‐
ent	study	is	part	of	a	larger	study	on	the	development	and	imple‐
mentation	of	an	online	decision	aid,	developed	in	accordance	with	
the	 International	 Patient	 Decision	 Aids	 Standards	 (Reumkens,	
Oudheusden,	 et	 al.,	 2018;	 Reumkens,	 Tummers,	 et	 al.,	 2018;	
Volk,	Llewellyn‐Thomas,	Stacey,	&	Elwyn,	2013).	In	this	study,	we	
report	 on	 the	 effects	 of	 the	 decision	 aid	 evaluated	 in	 a	 nation‐
wide	 pretest‐posttest	 study	 in	 all	 clinical	 genetic	 centres	 in	 the	
Netherlands.
2  | METHODS
2.1 | Participants and recruitment
Health	care	providers	(e.g.,	clinical	geneticists)	of	all	Clinical	Genetics	
Departments	 in	 the	 Netherlands	 recruited	 eligible	 couples	 during	
or	 after	 oncogenetic	 consultations	 from	 January	 2017	 to	 January	
2018.	Couples	were	 eligible	 for	 participation	 if	 one	partner	 had	 a	
pathogenic	variant	predisposing	for	autosomal	dominant	hereditary	
cancer,	 for	which	PND	and	PGD	are	 available	 in	 the	Netherlands.	
These	hereditary	cancers	include,	but	are	not	limited	to	carriers	and	
partners	of	carriers	of	the	following	types	of	hereditary	cancer:	he‐
reditary	breast	and	ovarian	cancer	(HBOC),	hereditary	colon	cancer	
(e.g.,	familial	adenomatous	polyposis	(FAP),	hereditary	non‐polypo‐
sis	colorectal	cancer	(HNPCC/Lynch	Syndrome),	Peutz–Jeghers	syn‐
drome,	multiple	endocrine	neoplasia	(MEN1/2),	retinoblastoma,	Von	
Hippel	Lindau	disease,	Li–Fraumeni	syndrome,	familial	atypical	mul‐
tiple	 mole/melanoma	 syndrome	 (FAMMM).	 Furthermore,	 couples	
levels	and	improved	realistic	expectations.	Level	of	deliberation	only	increased	for	partici‐
pants	with	lower	baseline	levels	of	deliberation.	Decision	self‐efficacy	increased	for	those	
with	low	baseline	scores,	whereas	those	with	high	baseline	scores	showed	a	reduction	at	
T2.	It	can	be	concluded	that	use	of	the	decision	aid	resulted	in	several	positive	outcomes	
indicative	of	informed	decision‐making.	The	decision	aid	is	an	appropriate	and	highly	ap‐
preciated	tool	to	be	used	in	addition	to	reproductive	counseling.
K E Y W O R D S
counseling,	decision	aid,	genetics,	hereditary	cancer,	informed	decision‐making,	oncology,	
patient	participation,	reproductive	decision‐making
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needed	 to	 have	 the	 intention	 to	 have	 children	 within	 the	 next	
5	years,	and	had	not	yet	made	a	definitive	decision	regarding	their	
preferred	reproductive	option.	Both	partners	had	to	be	18	years	or	
older	and	both	partners	needed	to	have	sufficient	knowledge	of	the	
Dutch	language.
2.2 | Procedures
Eligible	 couples	were	 provided	with	 an	 information	 brochure	 in‐
cluding	 a	 link	 to	 an	 online	 registration	 page.	 After	 registration,	
both	partners	received	an	informed	consent	form	by	e‐mail.	After	
providing	online	informed	consent,	both	partners	were	individually	
directed	to	an	online	(baseline)	questionnaire	(T0).	Questionnaires	
were	completed	separately	by	both	partners.	Subsequently,	 they	
received	a	personal	login	code	for	the	decision	aid.	It	was	allowed	
to	use	 the	decision	aid	 together.	Duration	of	use	and	page	visits	
were	 monitored.	 Immediately	 after	 use	 of	 the	 decision	 aid,	 par‐
ticipants	 were	 directed	 to	 the	 second	 questionnaire	 (T1).	 Two	
weeks	 after	 baseline,	 participants	were	 asked	 by	 e‐mail	 to	 com‐
plete	 a	 third	 questionnaire	 (T2).	 A	 reminder	was	 sent	 to	 partici‐
pants	who	did	not	complete	the	T1	questionnaire	within	1	day,	or	
the	 T2	 questionnaire	within	 7	days.	 An	 incentive	 of	 15	 euros	 in	
vouchers	was	provided	after	completion	of	all	questionnaires.	This	
study	was	approved	by	the	medical	ethics	committee	of	Maastricht	
UMC+	(METC	14‐5‐089).
2.3 | Content of the decision aid
An	extensive	explanation	of	the	developmental	process	and	the	spe‐
cific	content	of	the	decision	aid	are	provided	elsewhere	(Reumkens,	
Tummers,	et	al.,	2018).	Overall,	the	decision	aid	contained:
1.	 Information	about	the	risk	of	transmitting	the	pathogenic	variant	
to	 offspring	 and	 couples’	 options	 to	 have	 genetically	 related	
children.
2.	 Treatment	burden	of	reproductive	options	and	the	chances	of	dif‐
ferent	outcomes	(e.g.,	risk	of	miscarriage	after	PND)	presented	in	
multiple	suitable	formats	using	text	and	videos	(e.g.,	verbal,	and	
population	 diagrams)	 (Reumkens,	 Oudheusden,	 et	 al.,	 2018;	
Trevena	et	al.,	2013).
3.	 A	 comparative	 summary	 table	 of	 important	 features	 of	 each	
option.
4.	 Value	clarification	exercises	(VCE)	(Fagerlin	et	al.,	2013).	A	total	
of	18	statements	represents	values	and	motives	considered	im‐
portant	for	reproductive	decision‐making	(Derks‐Smeets	et	al.,	
2014).
5.	 By	linking	login	codes,	a	combined	overview	of	both	partners’	re‐
sponses	on	the	VCE	was	provided.
6.	 A	question	prompt	 sheet,	 providing	 examples	of	 questions	 and	
requests	for	additional	information	and	space	for	own	questions.
7.	 Information	 regarding	 the	 scientific	 resources	used	 to	underpin	
the	 decision	 aids	 content,	 the	 development	 team,	 funding	 re‐
sources,	and	contact	information.
2.4 | Instrumentation
Gender,	age,	educational	level,	carrier	status,	disease	type,	number	
of	children	and	couples’	planning	for	having	children	were	assessed	
at	 T0.	 Less	 than	 primary	 education,	 primary	 and	 lower	 secondary	
education	were	considered	as	low	education	levels.	Upper	second‐
ary	 and	 post‐secondary	 non‐tertiary	 education	 were	 considered	
as	middle	education	levels.	Tertiary	education	was	considered	as	a	
high	education	level.	At	T0	and	T2,	couples	were	also	asked	if	they	
already	 had	 a	 consultation	 with	 a	 healthcare	 provider.	 The	 main	
subject	of	this	consultation	(1	=	solely	focusing	on	the	reproductive	
options,	2	=	focusing	on	the	consequences	of	having	the	pathogenic	
variant,	 the	reproductive	options	concerned	only	a	small	part)	and	
the	profession	of	the	healthcare	provider	were	assessed.
The	 primary	 outcome	 measure,	 that	 is,	 participants’	 level	 of	
decisional conflict (at	 T0,	 T1,	 T2),	 was	 assessed	 by	 the	 Decisional	
Conflict	 Scale	 (O’Connor,	 1995a).	 The	 questionnaire	 contained	 16	
items	(Cronbach's	α	=	0.82).	Three	items	(α	=	0.90)	were	used	to	as‐
sess	values	of	uncertainty	about	the	decision,	three	items	(α	=	0.84)	
assessed	feelings	of	being	informed,	three	items	(α	=	0.90)	assessed	
personal	 beliefs	 regarding	 the	 reproductive	 options,	 three	 items	
(α	=	0.63)	assessed	 feelings	of	being	supported	 in	making	a	 repro‐
ductive	 decision,	 and	 four	 items	 (α	=	0.82)	 assessed	 the	 feeling	 of	
having	made	 an	 effective	 decision.	 Each	 item	was	 scored	 on	 a	 5‐
point	Likert	scale	ranging	from	0	(strongly	agree)	to	4	(strongly	dis‐
agree).	 Total	 scores	 ranged	 from	 0	 (no	 decisional	 conflict)	 to	 100	
(extremely	high	decisional	conflict)	(O'Connor,	1995a).	As	the	items	
in	the	effective	decision	subscale	could	not	be	completed	by	couples	
who	did	not	have	a	preferred	reproductive	option	 in	mind,	a	com‐
bined	score	was	also	calculated	for	the	four	other	subscales.	These	
12	 items	were	summed,	divided	by	12,	and	multiplied	by	25.	Total	
scores	ranged	from	0	(no	decisional	conflict)	to	100	(extremely	high	
decisional	conflict).
Participants’	current	knowledge of the three reproductive options 
(at	T0,	T1,	T2)	was	assessed	by	15	items	(Gietel‐Habets	et	al.,	2017).	
Three	questions	measured	participants’	knowledge	of	natural	con‐
ception	without	genetic	testing	(e.g.,	“When	opting	for	natural	con‐
ception,	 there	 is	a	50%	risk	of	 transmitting	the	pathogenic	variant	
to	offspring”;	1	=	correct,	2	=	incorrect,	3	=	not	sure),	five	questions	
measured	knowledge	of	PND	 (e.g.,	 “PND	 takes	place	during	preg‐
nancy”)	and	seven	questions	measured	knowledge	of	PGD	(e.g.,	“IVF	
is	necessary	to	perform	PGD”).	One	point	was	provided	to	each	cor‐
rectly	answered	question,	with	a	maximum	score	of	15.
Participants’	decision self‐efficacy (at	T0,	T1,	T2)	was	assessed	by	
the	Decision	Self‐Efficacy	Scale	(Bunn	&	O’Connor,	1996).	The	ques‐
tionnaire	contained	11	items	(Cronbach's	α	=	0.84),	each	scored	on	
a	5‐point	Likert	scale	ranging	from	0	(not	at	all	confident)	to	4	(very	
confident).	Total	scores	ranged	from	0	(extremely)	to	100	(extremely	
high)	(Bunn	&	O’Connor,	1996).
Realistic expectations regarding	the	reproductive	options	(T0,	T1,	
T2)	were	assessed	by	three	questions	(i.e.,	“What	is	the	extra	risk	of	
miscarriage	due	to	PND?”,	“What	 is	the	chance	of	pregnancy	after	
one	 IVF	 treatment	with	PGD?”,	 “What	 is	 the	 risk	of	 complications	
536  |     REUMKENS Et al.
with	 PGD?”).	 These	 questions	 contained	 8	 to	 11	 answer	 options.	
One	point	was	provided	to	each	correctly	answered	question,	with	a	
maximum	score	of	3	(O'Connor,	1995b).
Level of deliberation	(T0,	T1,	T2)	was	measured	by	the	Deliberation	
Scale	 (Van	den	Berg,	Timmermans,	Kate,	Vugt,	&	Wal,	2006).	The	
questionnaire	contained	six	items	(Cronbach's	α	=	0.90),	each	scored	
on	a	5‐point	Likert	scale	ranging	from	1	(totally	disagree)	to	5	(totally	
agree).	Total	scores	ranged	from	6	(low	level)	to	30	(high	level).
Evaluative items	 (T1).	 Participants	were	 asked	 to	 give	 an	 over‐
all	appreciation	score	for	the	decision	aid	at	a	scale	from	1–10	and	
to	indicate	in	open‐ended	questions	positive	and	negative	features	
and	 possibilities	 for	 improvements.	 Furthermore,	 10	 items	 (e.g.,	
perceived	efficiency	and	active	trust)	were	used	to	assess	user	per‐
ceptions	(Crutzen	et	al.,	2014)	including	two	items	of	the	system	us‐
ability	scale	(SUS)	(Brooke,	1996).	Each	item	was	scored	on	a	5‐point	
Likert	scale	ranging	from	0	(totally	disagree)	to	4	(totally	agree).
Lastly,	 participants’	 preparation for decision‐making	 (T1)	 was	
measured	by	the	Preparation	for	Decision	Making	Scale	(Graham	&	
O’Connor,	1995).	The	questionnaire	contained	10	items	(Cronbach's	
α	=	0.92),	each	scored	on	a	5‐point	Likert	scale	ranging	from	1	(to‐
tally	not)	to	5	(a	 lot).	Total	scores	ranged	from	0	(low	level)	to	100	
(high	level)	(Graham	&	O’Connor,	1995).
2.5 | Data analysis
Data	from	the	baseline	characteristics	were	analyzed	by	means	of	
descriptive	 statistics.	 Cohen's	 d	 was	 used	 to	 report	 effect	 sizes;	
Cronbach's	alpha	was	computed	 to	assess	 reliability.	Furthermore,	
an	intra‐couple	correlation	test	was	performed	before	evaluating	ef‐
fects.	We	compared	two	models	to	test	for	intra‐couple	correlation	
regarding	the	main	outcome	(decisional	conflict);	one	linear	mixed‐
effects	model	in	which	clustering	within	participants	over	time	and	
within	couples	was	corrected	for,	and	one	model	without	correction	
for	 clustering	within	 couples.	 Both	models	 yielded	 similar	 results,	
and	 a	 likelihood‐ratio	 test	 showed	 that	 correction	 for	 the	 cluster‐
ing	of	observations	within	couples	did	not	lead	to	a	better	model	fit	
(likelihood	ratio	=	0.00,	p	=	1.000).	Therefore,	all	participants	were	
analyzed	as	 independent	 from	each	other	and	therefore	we	chose	
to	 report	 the	 simpler	model	without	 correction	 for	 clustering	 and	
used	the	paired	sample	t	test	to	compute	differences	between	the	
first	and	subsequent	measurements.	For	in‐depth	analyses,	a	median	
split	was	performed	for	all	main	outcome	measures.	Analyses	were	
performed	using	IBM	spss	version	23	and	r	version	3.3.3.	p‐values	of	
<0.05	were	considered	to	indicate	statistical	significance.
3  | RESULTS
3.1 | Baseline characteristics
A	 total	 of	 140	 participants	 visited	 the	 registration	 page,	 of	which	
133	provided	informed	consent.	T0	was	completed	by	115	partici‐
pants	(86.5%)	and	110	participants	actually	visited	the	decision	aid	
(82.7%).	102	participants	completed	T1	(76.7%)	and	86	participants	
completed	T2	 (64.7%).	 80.4%	of	 the	participants	 filled	out	 the	T1	
questionnaire	immediately	after	visiting	the	decision	aid.	T2	was	on	
average	 filled	 out	 17.7	days	 after	 T0	 (SD =	10.05).	 The	mean	 time	
spent	using	the	decision	aid	was	27	min	 (range	5–95	min)	and	par‐
ticipants	viewed	a	mean	of	15	of	36	pages.	Table	1	shows	an	over‐
view	of	baseline	characteristics.	The	average	age	of	males	(M	=	31.6,	
SD =	3.6)	 was	 slightly	 higher	 compared	 to	 females	 (M	=	29.2,	
SD =	2.9).	 Most	 participants	 were	 highly	 educated	 (57.4%).	 The	
most	 frequently	 reported	hereditary	 cancer	 syndrome	was	HBOC	
(85.2%).The	majority	 of	 the	 participants	 (89%)	 already	 had	 a	 con‐
sultation	 in	 which	 the	 reproductive	 options	 were	 discussed.	 The	
consultation,	mostly	with	clinical	geneticists,	focused	mainly	on	the	
consequences	of	having	the	pathogenic	variant	(58.9%).	In	41.1%	of	
TA B L E  1  Baseline	characteristics	(N	=	115)
N Percentage
Gender
Male 51 44.3
Female 64 55.7
Age	(years)
Male 31.6	(SD	3.6)
Female 29.2	(SD	2.9)
Education
Low 11 9.6
Middle 38 33.0
High 66 57.4
Carrier	status
Male	carrier 36 31.3
Female carrier 79 68.7
Syndrome
HBOC 98 85.2
Lynch	syndrome 8 7.0
FAP 2 1.7
Li–Fraumeni	syndrome 2 1.7
Melanoma	syndrome 1 0.9
Hereditary	diffuse	gastric	cancer	
syndrome
2 1.7
Hereditary	leiomyomatosis	and	
renal cell cancer
2 1.7
Children
Yes 20 17.4
No 95 82.6
Planning	to	have	children
Trying	to	conceive	now 11 9.6
Within	2	years 70 60.9
Within	5	years 28 24.3
Not	sure	yet 4 3.5
Otherwise 2 1.7
Note.	 FAP:	 Familial	Adenomatous	Polyposis;	HBOC:	Hereditary	 breast	
and ovarian cancer.
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the	participants,	the	reproductive	options	had	been	the	main	topic.	
The	majority	of	the	participants	had	heard	of	PND	(73.0%)	and	PGD	
(89.6%)	before	participation	in	this	study	and	most	of	them	had	also	
received	information:	on	PND:	59.1%,	on	PGD:	69.6%.	A	little	over	
half	of	the	participants	(51.4%)	had	a	preferred	reproductive	option	
in	mind	at	baseline.
3.2 | Effects of the decision aid
As	 shown	 in	 Table	 2,	 total	 mean	 decisional conflict	 scores	 (range	
0–100)	 for	all	 five	subscales	significantly	decreased	 from	25.30	at	
baseline,	 to	 18.06	 at	 T1	 (Effect	 Size	 (ES)	=	0.73)	 and	 17.22	 at	 T2	
(ES	=	0.51).	 Total	 mean	 decisional	 conflict	 scores	 (range	 0–100)	
excluding	 the	 effective	 decision	 subscale,	 significantly	 decreased	
from	35.54	at	baseline,	to	25.33	at	T1	(ES	=	0.78)	and	26.31	at	T2	
(ES	=	0.44).	 In‐depth	 analyses	 (Table	 3)	 indicated	 that	 participants	
with	high	baseline	decisional	conflict	scores	(≥33),	excluding	the	ef‐
fective	decision	subscale,	had	a	significant	reduction	in	total	scores	
from	 baseline	 (M	=	51.35)	 to	 T1	 (M	=	34.46;	 ES	=	1.29)	 and	 T2	
(M	=	34.72;	 ES	=	0.80)	whereas	 participants	with	 low	 baseline	 de‐
cisional	conflict	scores	(<33)	only	showed	a	significant	reduction	in	
total	scores	at	T1	(ES	=	0.43).
As	 shown	 in	 Table	 2,	 the	 mean	 level	 of	 knowledge	 (range	
0–15)	 significantly	 increased	 from	 9.28	 at	 baseline,	 to	 13.16	 at	
T1	 (ES	=	−1.37)	 and	 12.63	 at	 T2	 (ES	=	−1.11).	 In‐depth	 analyses	
(Table	3)	indicated	that	knowledge	scores	significantly	increased	
for	 both	 participants	 with	 high	 (>10)	 and	 low	 (≤10)	 baseline	
knowledge	levels.
As	 shown	 in	 Table	 2,	Realistic expectations	 (range	 0–3)	 signifi‐
cantly	 increased	 from	0.72	 at	 baseline,	 to	 1.63	 at	 T1	 (ES	=	−0.85)	
and	1.08	at	T2	(ES	=	−0.37).	In‐depth	analyses	(Table	3)	showed	that	
realistic	expectations	were	significantly	increased	at	T1	and	T2	for	
participants	with	low	(≤1)	baseline	levels.
As	shown	in	Table	2,	with	a	mean	score	of	23.23	(range	6–30),	
the	 level	of	deliberation	was	relatively	high	at	baseline	and	did	not	
show	 an	 overall	 increase	 over	 time.	 However,	 in‐depth	 analyses	
(Table	3)	indicated	that	participants	with	lower	baseline	levels	of	de‐
liberation	(≤24)	showed	a	significant	increase	over	time	from	19.44	
at	baseline,	to	22.19	at	T1	(ES	=	−0.57)	and	22.27	at	T2	(ES	=	−0.53).	
No	effect	was	found	for	participants	with	higher	baseline	levels	of	
deliberation	(>24).
As	 shown	 in	 Table	 2,	 participants’	 decision self‐efficacy	 (range	
0–100)	 did	 not	 significantly	 increase	 from	 baseline	 (77.23)	 to	 T1	
(79.43;	ES	=	−0.16).	From	baseline	to	T2,	decision	self‐efficacy	sig‐
nificantly	 increased	 (M	=	79.81;	 ES	=	−0.23).	 In‐depth	 analyses	
(Table	 3)	 indicated	 that	 decision	 self‐efficacy	 of	 participants	 with	
low	baseline	scores	(≤75)	significantly	increased	from	67.00	at	base‐
line	to	73.07	at	T1	(ES	=	−0.47)	and	75.78	at	T2	(ES	=	−1.03),	whereas	
those	with	high	baseline	scores	(>75)	showed	a	significant	reduction	
in	self‐efficacy	at	T2	(ES	=	0.37).
3.3 | Depth of use of the decision aid
As	shown	in	Table	4,	both	users	with	 low	engagement	(≤15	pages)	
and	users	with	high	engagement	(>15	pages)	showed	decreased	de‐
cisional	 conflict	 scores,	 increased	knowledge	 levels,	 and	 increased	
TA B L E  3   In‐depth	analyses	for	main	outcome	measures	based	on	median	split	baseline	scores
T0 (baseline)
T1 (immediately 
after use of the 
decision aid)
T2 (2 weeks 
after baseline) T0–T1 T0–T2
Means (SD) Means (SD) Means (SD) T p ES T p ES
Decisional	conflict	(0–100)a
Low	baseline	(<33) 21.23	(9.77) 17.06	(11.13) 18.79	(16.00) 3.16 0.003 0.43 0.82 0.419 0.12
High	baseline	(≥33) 51.35	(13.36) 34.46	(15.10) 34.72	(19.78) 8.92 <0.001 1.29 5.16 <0.001 0.80
Knowledge	(0–15)
Low	baseline	(≤10) 6.93	(2.12) 12.70	(2.04) 12.11	(1.94) −14.04 <0.001 −2.07 −11.11 <0.001 −1.83
High	baseline	(>10) 11.21	(1.36) 13.54	(1.61) 13.02	(1.80) −10.38 <0.001 −1.39 −6.57 <0.001 −0.94
Realistic	expectations	(0–3)
Low	baseline	(≤1) 0.54	(0.50) 1.52	(1.11) 0.98	(0.89) −9.32 <0.001 −0.92 −4.85 <0.001 −0.48
High	baseline	(≥2) 2.15	(0.38) 2.46	(0.88) 1.85	(1.14) −1.17 0.264 −0.32 0.94 0.367 0.26
Level	of	deliberation	(6–30)
Low	baseline	(≤24) 19.44	(4.06) 22.19	(3.36) 22.27	(3.46) −3.22 0.003 −0.57 −2.68 0.013 −0.53
High	baseline	(>24) 27.22	(2.03) 26.48	(2.99) 26.39	(3.14) 1.43 0.166 0.27 1.30 0.208 0.27
Decision	self‐efficacy	(0–100)
Low	baseline	(≤75) 67.00	(7.42) 73.07	(15.16) 75.78	(13.59) −3.20 0.003 −0.47 −6.59 <0.001 −1.03
High	baseline	(>75) 88.18	(6.98) 86.11	(13.95) 82.45	(14.60) 0.92 0.361 0.14 2.22 0.033 0.37
aDecisional	conflict	scale	excluding	effective	decision	subscale.	
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realistic	expectations	at	T1	and	T2	(all	p's	<	0.05;	decisional	conflict	
in	high	engagement	group:	p	=	0.05).	Only	users	with	high	engage‐
ment	 showed	 increased	 levels	 of	 deliberation	 and	 increased	 deci‐
sional	self‐efficacy	at	T1	and	T2	(all	p's	<	0.05).
3.4 | Evaluation of the acceptability
The	mean	score	on	the	Preparation	for	Decision	Making	Scale	(range	
0–100)	 was	 62.3	 (SD =	19.6).	 A	 majority	 (82.2%)	 thought	 it	 was	
easy	 to	 find	 information	 in	 the	decision	aid	 (M	=	3.24,	SD =	0.81),	
found	 the	 various	 functions	 well	 integrated	 (84.2%,	 M	=	3.05,	
SD =	0.73),	 the	 information	 offered	 consistent	 (90.1%,	 M	=	3.43,	
SD =	0.70),	and	relevant	(82.6%,	M	=	3.41,	SD =	0.64).	Furthermore,	
participants	 found	 the	decision	aid	easy	 to	use	 (90.1%,	M	=	3.22,	
SD =	0.74)	 and	 trusted	 the	 offered	 information	 (94.1%,	M	=	3.40,	
SD =	0.63).	A	majority	 (80.2%)	 indicated	 that	 their	 awareness	 re‐
garding	the	available	options	increased	(M	=	2.97,	SD =	0.88),	93.5%	
thought	that	it	would	be	useful	to	develop	the	decision	aid	also	for	
other	hereditary	diseases	 (M	=	3.51,	SD =	0.66),	94.1%	would	rec‐
ommend	the	decision	aid	to	others	(M	=	3.51,	SD =	0.64)	and	80.2%	
(M	=	3.05,	SD =	0.89)	would	use	the	decision	aid	again	in	the	future.
Participants	 graded	 the	decision	 aid	 on	 a	 scale	 of	 1–10	with	 a	
mean	of	8.2	(SD =	0.94).	The	avoidance	of	medical	or	technical	terms	
was	 appreciated	 and	 the	 provided	 information	 was	 clear,	 neutral	
(i.e.,	not	guiding)	and	comprehensible.	Particularly,	the	value	clarifi‐
cation	exercises	and	informational	videos	were	appreciated,	but	the	
inclusion	of	narrative	stories,	 translation	 into	 the	English	 language	
and	making	it	better	compatible	for	use	on	mobile	devices	were	fre‐
quently	mentioned	improvements.
4  | DISCUSSION
To	our	knowledge,	this	is	the	first	study	to	report	on	the	effects	of	
a	decision	aid	to	support	persons	having	a	genetic	predisposition	to	
cancer	and	their	partners	in	decision‐making	regarding	their	repro‐
ductive	options.	Overall	 immediate	 (T0–T1)	and	 sustained	 (T0–T2)	
effects	 were	 found	 for	 decisional	 conflict,	 knowledge,	 and	 realis‐
tic	 expectations,	 only	 sustained	 effects	were	 found	 for	 decisional	
self‐efficacy.	No	main	 effects	were	 demonstrated	 for	 the	 level	 of	
deliberation.	However,	analyses	on	depth	of	use	of	the	decision	aid	
showed	 that	users	with	high	engagement	 showed	a	 significant	ef‐
fect	on	all	outcome	measures.	This	indicates	that	using	the	decision	
aid	 to	 its	 full	 extent	 positively	 influences	 all	main	 outcome	meas‐
ures.	Furthermore,	 in‐depth	analyses	 showed	both	 immediate	and	
sustained	effects	in	increasing	deliberation	among	those	with	lower	
baseline	 levels	of	deliberation.	This	 indicates	 that	 the	decision	aid	
is	 capable	 of	 encouraging	 deliberation	 among	 couples	who	 are	 in	
the	 early	 stages	 of	 decision‐making	 (Elwyn	&	Miron‐Shatz,	 2010).	
Furthermore,	in‐depth	analyses	showed	stronger	effects	for	partici‐
pants	with	 lower	baseline	 levels	of	 realistic	expectations,	self‐effi‐
cacy,	and	high	levels	of	decisional	conflict,	further	corroborating	the	
conclusion	that	the	decision	aid	particularly	supports	couples	with	
higher	needs	for	reproductive	decision	support.
A	notable	 finding	 is	 the	small	but	significant	 reduction	 in	deci‐
sional	self‐efficacy	scores	at	T2	for	participants	with	high	baseline	
scores,	indicating	that	use	of	the	decision	aid	introduced	some	un‐
certainty	among	those	who	felt	confident	 in	their	decision‐making	
ability	at	baseline.	A	solid	knowledge	base	is	regarded	as	a	prereq‐
uisite	 for	 informed	 decision‐making	 (Van	 den	 Berg	 et	 al.,	 2006).	
TA B L E  4  Effects	of	the	decision	aid	related	to	depth	of	use
T0 (baseline)
T1 (immediately after use 
of the decision aid)
T2 (2 weeks 
after baseline) T0–T1 T0–T2
Means (SD) Means (SD) Means (SD) T p ES T p ES
Decisional	conflict	(0–100)a
Low	engagementb 35.75	(21.12) 27.08	(15.83) 25.57	(16.99) 4.48 <0.001 0.63 3.93 <0.001 0.59
High	engagementc 35.55	(16.95) 23.58	(15.85) 27.79	(22.35) 6.58 <0.001 0.96 2.02 0.050 0.32
Knowledge	(0–15)
Low	engagement 9.22	(2.97) 12.37	(2.03) 11.95	(1.93) −7.59 <0.001 −1.06 −5.64 <0.001 −0.85
High	engagement 9.34	(2.64) 14.00	(1.14) 13.39	(1.62) −12.94 <0.001 −1.89 −8.96 <0.001 −1.45
Realistic	expectations	(0–3)
Low	engagement 0.64	(0.76) 1.45	(1.14) 1.08	(1.03) −5.49 <0.001 −0.75 −3.25 0.002 −0.45
High	engagement 0.84	(0.65) 2.08	(0.90) 1.24	(0.87) −9.81 <0.001 −1.39 −2.92 0.005 −0.41
Level	of	deliberation	(6–30)
Low	engagement 23.63	(4.72) 22.87	(4.33) 23.51	(3.99) 1.13 0.268 0.18 0.20 0.842 0.03
High	engagement 22.58	(4.23) 24.78	(2.64) 24.67	(2.72) −3.43 0.002 −0.57 −2.31 0.028 −0.42
Decision	self‐efficacy	(0–100)
Low	engagement 77.68	(13.42) 77.64	(16.85) 77.38	(15.19) 0.02 0.985 0.00 0.04 0.968 0.01
High	engagement 76.89	(11.44) 81.19	(14.21) 82.00	(12.96) −2.67 0.010 −0.39 −3.65 0.001 −0.60
aDecisional	conflict	scale	excluding	effective	decision	subscale.	b≤15	pages.	c>15	pages.	
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Post‐hoc	 analyses	 indicated	 that	 baseline	 knowledge	 levels	 were	
identical	for	participants	with	low	and	high	baseline	scores	of	deci‐
sion	 self‐efficacy	 (M	=	9.21	 respectively	M	=	9.20),	 suggesting	 that	
the	expressed	confidence	in	decision‐making	was	not	based	on	ade‐
quate	knowledge	levels.	As	the	decision	aid	had	such	strong	effects	
on	knowledge	of	reproductive	options,	the	information	provided	in	
the	decision	aid	may	have	resulted	in	the	identification	of	possible	
misconceptions	or	knowledge	gaps,	and	possibly	a	 further	 realiza‐
tion	of	the	complexity	of	the	decision	among	those	with	high	base‐
line	 decisional	 self‐efficacy.	 This	 finding	 furthermore	 emphasizes	
the	importance	of	embedding	the	decision	aid	in	a	counseling	pro‐
cess	with	adequate	follow‐up	counseling	for	couples	who	are	still	in	
need	of	professional	support	after	viewing	the	decision	aid.
4.1 | Study limitations
The	use	of	a	pretest‐posttest	design	 restricts	 the	 internal	validity,	
as	maturation	and	history	effects	as	well	as	effects	due	to	repeated	
testing	cannot	be	controlled	 for.	Although	 the	execution	of	meas‐
urements	immediately	before	and	after	the	use	of	the	decision	aid	
minimizes	the	likelihood	of	bias,	possible	interference	of	other	fac‐
tors,	such	as	use	of	other	information	sources	or	different	exposure	
to	impactful	counseling,	cannot	be	excluded.	Furthermore,	the	ma‐
jority	of	the	participants	did	not	use	the	complete	decision	aid.	This	
could	be	due	to	the	length	and	amount	of	information	in	the	decision	
aid.	Further	investigation	of	possible	consequences	of	abbreviating	
the	decision	 aid	 on	 the	 effectiveness	 of	 the	decision	 aid	 is	 there‐
fore	recommended.	Lastly,	as	urgency	of	child	wish	is	not	standardly	
registered	in	all	clinical	genetic	centres	and	hospital	regulations	pro‐
hibited	the	distribution	of	non‐participating	 individuals,	we	cannot	
provide	an	estimate	of	the	number	of	eligible	couples	and	we	were	
unable	to	calculate	a	response	rate.
4.2 | Research recommendations
The	majority	of	the	participants	in	this	study	were	highly	educated	
(57%).	Although	this	 is	 in	line	with	general	characteristics	of	onco‐
genetic	counselees	(Giessen	van	der,	2017),	this	number	is	notably	
high	 compared	 to	 the	 numbers	 in	 the	 general	 Dutch	 population	
(30%)	 (CBS,	2016).	 This	 further	 exposes	 the	need	 for	 research	on	
measures	 to	 improve	 referral	of	patients	with	a	 lower	educational	
background.	Furthermore,	as	the	reproductive	decision	is	often	not	
implemented	within	 several	months	 after	 reproductive	 counseling	
or	after	reviewing	the	decision	aid,	a	long‐term	follow‐up	to	measure	
decision	adherence	(e.g.,	18	months	after	reviewing	the	decision	aid)	
would	be	useful.
4.3 | Practice implications
Use	of	 the	decision	aid	 resulted	 in	several	positive	outcomes	 in‐
dicative	of	informed	decision‐making	which	may	lessen	the	nega‐
tive	 psychological	 impact	 of	 decision‐making	 on	 couples’	 daily	
life	and	well‐being.	The	decision	aid	 is	an	appropriate	and	highly	
appreciated	tool	to	be	used	in	addition	to	reproductive	counseling.	
In‐depth	analyses	showed	that	the	couples	who	are	in	the	highest	
need	of	reproductive	decision	support	are	those	who	are	the	most	
supported	by	the	decision	aid	which	increases	the	overall	impact	
of	 the	 decision	 aid.	Currently,	we	 are	 conducting	 an	 explorative	
implementation	study	to	clarify	optimal	timing	of	providing	the	de‐
cision	aid	and	how	to	incorporate	the	decision	aid	in	daily	practice.	
To	further	increase	the	impact	of	the	decision	aid,	the	content	of	
the	tool	will	be	adapted	to	other	hereditary	conditions.	Supporting	
Information	Data	S1–S3.
5  | CONCLUSION
The	current	findings	indicate	that	the	decision	aid	can	be	effective	
in	supporting	persons	having	a	genetic	predisposition	to	cancer	and	
their	partners	 in	making	an	 informed	decision	regarding	reproduc‐
tive	options.	 Further	 research	 is	 needed	 to	 indicate	prolonged	ef‐
fects	on	informed	decision‐making	and	informed	choice.
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